$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

$rigl Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155837024007041 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$36.84M	$29.53M
YoY Change	37.03%	13.29%
Cost Of Revenue	$2.807M	$2.025M
YoY Change	161.12%	107.27%
Gross Profit	$34.03M	$27.51M
YoY Change	31.86%	9.63%
Gross Profit Margin	92.38%	93.14%
Selling, General & Admin	$28.05M	$28.45M
YoY Change	6.62%	2.6%
% of Gross Profit	82.41%	103.42%
Research & Development	$5.540M	$6.026M
YoY Change	16.09%	-40.27%
% of Gross Profit	16.28%	21.91%
Depreciation & Amortization	$613.0K	$400.0K
YoY Change	107.09%	12.04%
% of Gross Profit	1.8%	1.45%
Operating Expenses	$33.59M	$34.48M
YoY Change	8.07%	-8.84%
Operating Profit	$447.0K	-$6.966M
YoY Change	-108.49%	-45.26%
Interest Expense	$2.029M	$1.874M
YoY Change	-252.21%	55.65%
% of Operating Profit	453.91%
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.030M	-$11.78M
YoY Change	-84.39%	-12.99%
Income Tax
% Of Pretax Income
Net Earnings	-$1.030M	-$8.247M
YoY Change	-84.39%	-39.07%
Net Earnings / Revenue	-2.8%	-27.92%
Basic Earnings Per Share	-$0.06	-$0.05
Diluted Earnings Per Share	-$0.06	-$0.05
COMMON SHARES
Basic Shares Outstanding	175.4M	175.4M
Diluted Shares Outstanding	17.55M	175.2M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.10M	$49.55M
YoY Change	-23.7%	-15.53%
Cash & Equivalents	$36.05M	$25.57M
Short-Term Investments	$13.05M	$23.98M
Other Short-Term Assets	$8.658M	$8.845M
YoY Change	74.31%	12.43%
Inventory	$8.059M	$6.579M
Prepaid Expenses
Receivables	$28.90M	$27.51M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$94.72M	$92.49M
YoY Change	-6.15%	-13.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$115.0K	$140.0K
YoY Change	-90.51%	-52.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.735M	$4.318M
YoY Change	775.23%	696.68%
Total Long-Term Assets	$33.69M	$34.03M
YoY Change	108.37%	104.53%
TOTAL ASSETS
Total Short-Term Assets	$94.72M	$92.49M
Total Long-Term Assets	$33.69M	$34.03M
Total Assets	$128.4M	$126.5M
YoY Change	9.67%	2.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.130M	$9.276M
YoY Change	16.98%	47.36%
Accrued Expenses	$17.62M	$15.52M
YoY Change	-2.37%	-14.49%
Deferred Revenue	$1.355M	$1.355M
YoY Change	0.0%	-1.02%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$14.78M
YoY Change
Total Short-Term Liabilities	$58.65M	$73.20M
YoY Change	33.22%	60.81%
LONG-TERM LIABILITIES
Long-Term Debt	$59.69M	$44.91M
YoY Change	0.2%	-24.5%
Other Long-Term Liabilities	$39.98M	$39.98M
YoY Change	-3.91%	-4.95%
Total Long-Term Liabilities	$39.98M	$39.98M
YoY Change	-60.49%	-4.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$58.65M	$73.20M
Total Long-Term Liabilities	$39.98M	$39.98M
Total Liabilities	$158.3M	$158.2M
YoY Change	9.03%	6.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.417B	-$1.416B
YoY Change	1.01%	1.42%
Common Stock	$1.387B	$1.384B
YoY Change	0.9%	0.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$29.91M	-$31.67M
YoY Change
Total Liabilities & Shareholders Equity	$128.4M	$126.5M
YoY Change	9.67%	2.35%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$1.030M	-$8.247M
YoY Change	-84.39%	-39.07%
Depreciation, Depletion And Amortization	$613.0K	$400.0K
YoY Change	107.09%	12.04%
Cash From Operating Activities	$302.0K	-$5.013M
YoY Change	-94.91%	23.05%
INVESTING ACTIVITIES
Capital Expenditures	$222.0K	$138.0K
YoY Change		-99.08%
Acquisitions
YoY Change
Other Investing Activities	$11.15M	$451.0K
YoY Change	275.45%	-97.14%
Cash From Investing Activities	$10.93M	$313.0K
YoY Change	267.98%	-59.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-752.0K	-2.512M
YoY Change	101.61%	-113.14%
NET CHANGE
Cash From Operating Activities	302.0K	-5.013M
Cash From Investing Activities	10.93M	313.0K
Cash From Financing Activities	-752.0K	-2.512M
Net Change In Cash	10.48M	-7.212M
YoY Change	22.89%	-145.57%
FREE CASH FLOW
Cash From Operating Activities	$302.0K	-$5.013M
Capital Expenditures	$222.0K	$138.0K
Free Cash Flow	$80.00K	-$5.151M
YoY Change	-98.65%	-72.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175203000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173568000
CY2024Q1	rigl	Net Sublease Income Expense NetSubleaseIncomeExpense
CY2023Q1	rigl	Net Sublease Income Expense NetSubleaseIncomeExpense
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	rigl	Collaborative Arrangement Revenue Recognized CollaborativeArrangementRevenueRecognized	20000000
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	0-29889
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3248524
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	611 Gateway Boulevard, Suite 900,
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2024Q1	dei	City Area Code CityAreaCode	650
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	624-1100
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	RIGL
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	175406146
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25574000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32786000
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	23976000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	24147000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27512000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30550000
CY2024Q1	us-gaap	Inventory Net InventoryNet	6579000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5522000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8845000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6261000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	92486000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	99266000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	140000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165000
CY2024Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	28863000
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	13878000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	712000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	861000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4318000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3055000
CY2024Q1	us-gaap	Assets Assets	126519000
CY2023Q4	us-gaap	Assets Assets	117225000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9276000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7142000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5246000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8676000
CY2024Q1	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	4127000
CY2023Q4	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	3513000
CY2024Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	15222000
CY2024Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	16045000
CY2023Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	15684000
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	14780000
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	7229000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5435000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5334000
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1355000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1355000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	709000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	692000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1003000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3642000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	73198000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53267000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	285000
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	44910000
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	52373000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39982000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39944000
CY2024Q1	us-gaap	Liabilities Liabilities	158190000
CY2023Q4	us-gaap	Liabilities Liabilities	145869000
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	175000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	175000
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1383956000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1378723000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1415797000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1407550000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-31671000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-28644000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126519000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	117225000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29534000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26070000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2025000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	977000
CY2024Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6026000
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10089000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28449000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27729000
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	36500000
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	38795000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6966000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12725000
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	593000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	393000
CY2024Q1	us-gaap	Interest Expense InterestExpense	1874000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1204000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8247000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13536000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	175203000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173568000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8247000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13536000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	126000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8260000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13410000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-28644000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8247000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	89000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5144000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-31671000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-13616000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13536000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	126000
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2768000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-24257000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-8247000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-13536000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5134000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2758000
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-347000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	357000
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	205000
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	68000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3038000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10954000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2310000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1949000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2584000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-392000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-98000
CY2024Q1	rigl	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	149000
CY2023Q1	rigl	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	807000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2134000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1213000
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3430000
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3205000
CY2024Q1	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	614000
CY2023Q1	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	-768000
CY2024Q1	rigl	Revenue Reserves And Refund Liability RevenueReservesAndRefundLiability	361000
CY2023Q1	rigl	Revenue Reserves And Refund Liability RevenueReservesAndRefundLiability	1943000
CY2024Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	101000
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1389000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-168000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-854000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1252000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5013000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4074000
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	8250000
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	15650000
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7799000
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	138000
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000000
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	127000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	313000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	777000
CY2023Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	19950000
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	89000
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1000
CY2024Q1	rigl	Payment Of Cost Share To Collaboration Partner PaymentOfCostShareToCollaborationPartner	2601000
CY2023Q1	rigl	Payment Of Cost Share To Collaboration Partner PaymentOfCostShareToCollaborationPartner	828000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2512000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19123000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7212000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	15826000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32786000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24459000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25574000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40285000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1684000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1011000
CY2024Q1	rigl	Intangible Assets Incurred But Not Yet Paid IntangibleAssetsIncurredButNotYetPaid	15222000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p>
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	49600000
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41453000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38242000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29534000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26070000
CY2024Q1	rigl	Sales Discounts And Allowances SalesDiscountsAndAllowances	12300000
CY2023Q1	rigl	Sales Discounts And Allowances SalesDiscountsAndAllowances	9200000
CY2023Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	15684000
CY2024Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	12267000
CY2024Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	11906000
CY2024Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	16045000
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	12145000
CY2023Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	9223000
CY2023Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	7280000
CY2023Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	14088000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1508000
CY2024Q1	rigl	Inventory And Inventory Reported As Other Assets InventoryAndInventoryReportedAsOtherAssets	10313000
CY2023Q4	rigl	Inventory And Inventory Reported As Other Assets InventoryAndInventoryReportedAsOtherAssets	7993000
CY2024Q1	us-gaap	Inventory Net InventoryNet	6579000
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	49550000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56933000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25574000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32786000
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	23976000
CY2024Q1	rigl	Contingent Payments Under Agreement ContingentPaymentsUnderAgreement	1300000000
CY2021Q2	rigl	Collaborative Arrangement Upfront Fee Received CollaborativeArrangementUpfrontFeeReceived	125000000.0
CY2024Q1	rigl	Right To Opt Out Of Agreement Number Of Periods RightToOptOutOfAgreementNumberOfPeriods	2
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5134000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2758000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	375000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7129161
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3918000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4609000
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	5120000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1876000
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1275000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5522000
CY2024Q1	rigl	Inventory Reported As Other Assets InventoryReportedAsOtherAssets	3734000
CY2023Q4	rigl	Inventory Reported As Other Assets InventoryReportedAsOtherAssets	2471000
CY2024Q1	rigl	Inventory And Inventory Reported As Other Assets InventoryAndInventoryReportedAsOtherAssets	10313000
CY2023Q4	rigl	Inventory And Inventory Reported As Other Assets InventoryAndInventoryReportedAsOtherAssets	7993000
CY2024Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	700000
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	0
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	30360000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1497000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1122000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28863000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13878000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1764000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2351000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2351000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2351000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2351000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17695000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28863000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	24147000
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	49550000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56933000
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33945000
CY2024Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33940000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	38993000
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	39001000
CY2024Q1	rigl	Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod	P58D
CY2023	rigl	Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod	P82D
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	31
CY2024Q1	rigl	Investments Credit Loss Expense InvestmentsCreditLossExpense	0
CY2023Q4	rigl	Investments Credit Loss Expense InvestmentsCreditLossExpense	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	27990000
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	8000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60000000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60000000
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	310000
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	398000
CY2024Q1	rigl	Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts	59690000
CY2023Q4	rigl	Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts	59602000
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	14780000
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	7229000
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	44910000
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	52373000
CY2024Q1	us-gaap	Loans Payable LoansPayable	59690000
CY2023Q4	us-gaap	Loans Payable LoansPayable	59602000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	7500000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	30000000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	22500000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	60000000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	166000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	612000
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	28000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	72000
CY2024Q1	us-gaap	Lease Cost LeaseCost	194000
CY2023Q1	us-gaap	Lease Cost LeaseCost	684000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	184000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	996000
CY2023Q1	rigl	Fixed Sublease Expense FixedSubleaseExpense	365000
CY2023Q1	rigl	Variable Sublease Expense VariableSubleaseExpense	77000
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	442000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	555000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	301000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	856000

Files In Submission

Name	View Source	Status
0001558370-24-007041-index-headers.html	Edgar Link	pending
0001558370-24-007041-index.html	Edgar Link	pending
0001558370-24-007041.txt	Edgar Link	pending
0001558370-24-007041-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20240331.xsd	Edgar Link	pending
rigl-20240331x10q.htm	Edgar Link	pending
rigl-20240331x10q004.jpg	Edgar Link	pending
rigl-20240331xex10d1.htm	Edgar Link	pending
rigl-20240331xex10d2.htm	Edgar Link	pending
rigl-20240331xex10d3.htm	Edgar Link	pending
rigl-20240331xex10d4.htm	Edgar Link	pending
rigl-20240331xex31d1.htm	Edgar Link	pending
rigl-20240331xex31d2.htm	Edgar Link	pending
rigl-20240331xex32d1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rigl-20240331_def.xml	Edgar Link	unprocessable
rigl-20240331_lab.xml	Edgar Link	unprocessable
rigl-20240331_pre.xml	Edgar Link	unprocessable
rigl-20240331x10q_htm.xml	Edgar Link	completed
rigl-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

2024 Q2 Form 10-Q Financial Statement

#000155837024007041 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL RIGEL PHARMACEUTICALS INC Stock $rigl

2024 Q2 Form 10-Q Financial Statement

#000155837024007041 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl